Literature DB >> 3974889

Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs.

B O Khatri, M P McQuillen, G J Harrington, D Schmoll, R G Hoffmann.   

Abstract

Fifty-four patients with chronic progressive multiple sclerosis received prednisone plus oral low-dose cyclophosphamide and either true plasmapheresis (PP) or "sham" PP weekly for 20 weeks in a double-blind controlled study. Immunosuppressive drug therapy alone (sham PP group, n = 29) was associated with improvement (greater than or equal to one step in Kurtzke Disability Status Scale [DSS]; mean change of 1.5) in 8 and stabilization of MS in 18 patients, with this status sustained in 23 patients at follow-up, 11 months after entry. In contrast, 14 of 26 patients who received "true" PP improved (greater than or equal to one step in DSS; mean change of 2.6), and 11 more were stable, with these changes sustained in 23 of 26 patients at follow-up. These differences, overall, between the PP and sham PP groups were significant at p less than 0.007.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3974889     DOI: 10.1212/wnl.35.3.312

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

Review 1.  [Plasma exchange as a therapeutic option in neurological disorders].

Authors:  H C Lehmann; H P Hartung; G R Hetzel; B C Kieseier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

Review 2.  Cyclophosphamide for multiple sclerosis.

Authors:  L La Mantia; C Milanese; N Mascoli; R D'Amico; B Weinstock-Guttman
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 3.  Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Man Mohan Mehndiratta; Avinash Chandra Singh
Journal:  Curr Allergy Asthma Rep       Date:  2007-07       Impact factor: 4.806

4.  Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis.

Authors:  Ralf A Linker; Andrew Chan; Martin Sommer; Michael Koziolek; Gerhard-Anton Müller; Walter Paulus; Ralf Gold
Journal:  J Neurol       Date:  2007-08-16       Impact factor: 4.849

Review 5.  Corticosteroids and plasma exchange in multiple sclerosis.

Authors:  Hayretin Tumani
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

6.  Immunological treatment of multiple sclerosis. II.

Authors:  R A Hughes
Journal:  J Neurol       Date:  1986-04       Impact factor: 4.849

7.  Lymphocytoplasmapheresis in multiple sclerosis: one-year results in 6 patients.

Authors:  A Ghezzi; G A Zaffaroni; D Caputo; R Guaschino; D Alesso; P Gasco; R Montanini; C L Cazzullo
Journal:  Ital J Neurol Sci       Date:  1986-02

Review 8.  Plasma exchange in neurological diseases.

Authors:  P O Behan; W M Behan
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-01

Review 9.  Immunotherapy for multiple sclerosis.

Authors:  R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

10.  Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.

Authors:  B O Khatri; S Man; G Giovannoni; A P Koo; J-C Lee; B Tucky; F Lynn; S Jurgensen; J Woodworth; S Goelz; P W Duda; M A Panzara; R M Ransohoff; R J Fox
Journal:  Neurology       Date:  2009-02-03       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.